Interaction entre Cénobamate et Clobazam

Phenobarbital and Clobazam: Reduce dosage as needed when used concomitantly with XCOPRI.

…phenobarbital ↑ plasma concentrations Because of a potential for an increase in the risk of adverse reactions from these drugs, consider a reduction in dosage of phenobarbital or clobazam, as clinically appropriate, when used concomitantly with XCOPRI. desmethylclobazam, the active metabolite of clobazam ↑ plasma concentrations CYP2B6 Substrates ↓ plasma concentrations…

Concomitant use with other CNS depressants or alcohol may have additive effects.

Anyone considering prescribing XCOPRI or any other AED must balance this risk with the risk of untreated illness.

Patients should be carefully observed for signs of central nervous system (CNS) depression, such as somnolence and sedation, when XCOPRI is used with other drugs with sedative properties because of potential additive effects.

Risk may be increased with concomitant use of other CNS depressants ( 5.4 , 5.5 )

Prescribers should monitor patients for somnolence and sedation, particularly with concomitant use of other central nervous system depressants.

Strong or Moderate CYP2C19 Inhibitors: Dosage adjustment of SYMPAZAN ® may be necessary ( 7.4 )

Therefore, caution patients or their caregivers against simultaneous use with other CNS depressant drugs or alcohol, and caution that the effects of other CNS depressant drugs or alcohol may be potentiated [see Warnings and Precautions (5.4) ].

Effect of Other Drugs on SYMPAZAN ® Strong and Moderate Inhibitors of CYP2C19 Coadministration with strong or moderate inhibitors of CYP2C19 may result in increased exposure to N-desmethylclobazam, the active metabolite of clobazam.